RARE Ultragenyx Pharmaceutical Inc.

73.01
+0.04  (0.05%)
Previous Close 72.97
Open 72.93
Price To book 6.41
Market Cap 2.98B
Shares 40,859,000
Volume 371,415
Short Ratio 9.31
Av. Daily Volume 602,695

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17527355
  2. CT ORDER - Confidential treatment order 17516241
  3. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 162044936
  4. 8-K - Current report 162031355
  5. 424B7 - Prospectus [Rule 424(b)(7)] 162031226

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. BLA filing due 1H 2017.
rhGUS
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 to be initiated 1H 2017.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data due 2H 2017.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3 enrolment completed July 2016. Data due 1H 2017.
KRN23
X-Linked Hypophosphatemia (XLH) - adult
Interim data released April 2016. Additional data released September 2016.
KRN23
Tumor-induced osteomalacia (TIO)
Phase 3 enrollment commenced October 2016.
KRN23
X-Linked Hypophosphatemia (XLH) - pediatric
Phase 2 initiated March 2014. Seizure data due 1Q 2017.
UX007 (triheptanoin)
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase 2 interim data released October 2015. 78-week data released November 30, 2016. Phase 3 planned for 2017.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Latest News

  1. Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
  2. Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : January 5, 2017
  3. Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency
  4. Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency(106KB)
  5. Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency
  6. Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency
  7. Ultragenyx to Present at J.P. Morgan Healthcare Conference
  8. Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 23, 2016
  9. ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : December 14, 2016
  10. Ultragenyx Pharmaceutical, Inc. – Value Analysis (NASDAQ:RARE) : December 13, 2016
  11. Should You Buy MB Financial, Inc. (MBFI)?
  12. Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 12, 2016
  13. Hedge Funds Are Dumping Ultragenyx Pharmaceutical Inc (RARE)
  14. ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  15. Ultragenyx Announces Positive Data from Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients
  16. Ultragenyx (RARE) Reports Positive Phase II Study on UX007
  17. Ultragenyx Announces Positive Data from Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients
  18. Blog Coverage Lion Biotechnologies Signs a New Manufacturing Services Agreement with WuXi AppTec for its Cell Therapy Products
  19. ULTRAGENYX PHARMACEUTICAL INC. Financials
  20. ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

SEC Filings

  1. CT ORDER - Confidential treatment order 17527355
  2. CT ORDER - Confidential treatment order 17516241
  3. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 162044936
  4. 8-K - Current report 162031355
  5. 424B7 - Prospectus [Rule 424(b)(7)] 162031226
  6. 8-K - Current report 161995589
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161979571
  8. 8-K - Current report 161978125
  9. 8-K - Current report 161829167
  10. 424B7 - Prospectus [Rule 424(b)(7)] 161822246